Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07428889 · ClinicalTrials.gov registry record · NA

Nicotinamide Adenine Dinucleotide Responses to a Nutritional Supplement

A NA study of Healthy Adult, sponsored by Shaklee Corporation.

Recruiting
Registry status
NA
Development phase
34
Enrollment target
1
Study location

NCT07428889 is a NA study of Healthy Adult that is actively recruiting participants, run by Shaklee Corporation. The registered enrollment target is 34 participants, below the 70-participant average among 8 other Healthy Adult trials with a reported enrollment target (51% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07428889, a NA study of Healthy Adult, is actively recruiting participants, sponsored by Shaklee Corporation.

RECRUITING
Registry status
NA
Development phase
34 participants
Enrollment target
1
Study location

Study Summary

The objective of this study is to evaluate nicotinamide adenine dinucleotide (NAD+) in response to a proprietary nutritional supplement in generally healthy adults, compared to placebo.

Conditions Studied

Interventions

  • DIETARY_SUPPLEMENT Placebo Supplement
  • DIETARY_SUPPLEMENT Proprietary Nutritional Supplement

Study Locations (1)

Illinois

  • Biofortis Clinical Research - Addison

Trial Details

FieldValue
Enrollment Target 34 participants
Start Date 2026-02
Est. Completion 2026-06
Phase NA

Sponsor

Shaklee Corporation

3 total trials

What the Registry Record Tells You About NCT07428889

The ClinicalTrials.gov registry entry for NCT07428889 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 70-participant average among 8 other Healthy Adult trials with a reported enrollment target (51% lower). The listed sponsor is Shaklee Corporation, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy Adult appearing as the primary indexed condition, and to 2 interventions - of which Placebo Supplement is the first listed.

NCT07428889 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.

Frequently Asked Questions

What is clinical trial NCT07428889 about?

NCT07428889 is a clinical study titled "Nicotinamide Adenine Dinucleotide Responses to a Nutritional Supplement". The objective of this study is to evaluate nicotinamide adenine dinucleotide (NAD+) in response to a proprietary nutritional supplement in generally healthy adults, compared to placebo.

What is the current status of trial NCT07428889?

This trial is currently recruiting. It is a NA study. The enrollment target is 34 participants. The study started on 2026-02. Estimated completion is 2026-06.

What conditions does trial NCT07428889 study?

This clinical trial studies the following conditions: Healthy Adult.

What interventions are being tested in trial NCT07428889?

The interventions under investigation include: Placebo Supplement (DIETARY_SUPPLEMENT), Proprietary Nutritional Supplement (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT07428889?

This trial is sponsored by Shaklee Corporation, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07428889 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy Adult

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.